ClinicalTrials.gg
RecruitingNCT06971731Updated Oct 21, 2026

A Study of JNT-517 in Participants With Phenylketonuria (PKU)

A Phase 3 interventional study of JNT-517 and JNT-517 Matching Placebo in Phenylketonuria, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Recruiting at 26 sites in 10 countries. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Updated Oct 21, 2026Eligibility revisedPrimary outcomes revised+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies in Phenylketonurias with a site in United States — 16 open to participants now, 21 under way, 4 of them phase 3. Phenylketonurias · United States.

Planned enrollment
11th of 63
120 · median 33
Started
2025
with 5 others
Phase 3
16 of 93
3 open now
Primary completion
2028-03
later than 13 of 20 live
Registered
87th of 93
by date
Lead sponsor
5 of 93
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 93 studies in Phenylketonurias with a site in United States, this one is the 11th largest by planned enrollment of the 63 interventional ones that give a count, is one of 6 that started in 2025, is one of 16 in phase 3, reaches primary completion later than 13 of the 20 other live ones, and was the 87th registered.

Phenylketonurias

191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.

Browse Phenylketonurias studies →

Open to participants now

16 of the 93 studies in Phenylketonurias with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: 4 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Phenylketonurias with a site in United States, or all of them as a file.
02

Study summary

This Phase 3 study will evaluate the safety, effectiveness, tolerability, and how the body processes JNT-517 in children, adolescents, and adults with phenylketonuria.

Participants will be randomly assigned to receive either JNT-517 or placebo during an initial 6-week treatment period. After this period, eligible participants will receive JNT-517 for an additional 46 weeks.

03

Conditions studied

  • Phenylketonuria

Browse trials for

Keywords

  • Phenylketonuria
  • PKU
04

Who can participate

The criteria were revised on the registry on Oct 21, 2026. See what changed

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged 4 years or older.
  2. Diagnosed with phenylketonuria.
  3. Have phenylalanine levels that meet study requirements.
  4. Meet study-specific requirements regarding current treatment for phenylketonuria.
  5. Willing and able to follow study dietary requirements.
  6. Weigh at least 12.5 kilograms.
  7. If able to become pregnant or father a child, willing to follow the study's requirements.
  8. Any ongoing mental health condition must be stable before entering the study.
  9. Able to provide (or have consent provided by a parent or legal guardian, when applicable) and comply with study procedures.

Exclusion criteria

Exclusion Criteria:

Participants will be excluded from the study if any of the following criteria are met:

  1. Significant medical condition that, in the investigator's opinion, could make participation unsafe or interfere with study participation.
  2. Significant liver disease or impaired kidney function.
  3. Certain eye conditions, including significant cataracts.
  4. Active infection requiring medical evaluation.
  5. History of certain cancers within the past 5 years.
  6. Allergy or to JNT-517 or its ingredients.
  7. Prior treatment with JNT-517.
  8. Recent participation in another study or receipt of an investigational treatment that does not meet study requirements.
  9. Use of medications that are not permitted during the study.
  10. Abnormal laboratory or heart test results that would make study participation inappropriate.
  11. Conditions that could affect the absorption of oral study medication.
  12. History of recent substance or alcohol abuse.
  13. Unwillingness to follow study requirements, including restrictions on intentional weight loss.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    JNT-517 - High Dose

    Participants will receive JNT-517 orally, twice daily (BID), with dosing determined by age, for 6 weeks in Period 1, followed by JNT-517 orally, BID for 46 weeks in Period 2.

    Drug: JNT-517

  • Experimental
    JNT-517 - Low Dose

    Participants will receive JNT-517 orally, BID, with dosing determined by age, for 6 weeks in Period 1, followed by JNT-517 orally for 46 weeks in Period 2.

    Drug: JNT-517

  • Placebo comparator
    Placebo

    Participants will receive JNT-517 matching placebo orally, BID for 6 weeks in Period 1, followed by JNT-517 orally, BID for 46 weeks in Period 2.

    Drug: JNT-517 Matching Placebo

Interventions

  • JNT-517 orally

  • DrugJNT-517 Matching Placebo

    JNT-517 matching placebo orally

06

What researchers measure

Primary outcomes

  1. Absolute Change in Plasma Phenylalanine (Phe) From Baseline to the Mean of Weeks 2, 4, and 6 in the JNT-517 High Dose BID Dose Group at End of Period 1

    Time frame: Baseline to End of Period 1 (Week 6)

Secondary outcomes

  1. Percent Change in Plasma Phe From Baseline to the Mean of Weeks 2, 4, and 6 in the JNT-517 High Dose BID Group at End of Period 1

    Time frame: Baseline to End of Period 1 (Week 6)

  2. Percentage of Participants Achieving Plasma Phe Less Than (<) 600 Micromoles per Liter (µmol/L) at End of Period 1 Among Participants With Baseline ≥600 µmol/L in the High Dose BID Group

    Time frame: Baseline to End of Period 1 (Week 6)

  3. Percentage of Participants Achieving Plasma Phe <360 µmol/L at End of Period 1 in the High Dose BID Group

    Time frame: Baseline to End of Period 1 (Week 6)

  4. Percentage of Participants Achieving Plasma Phe <600 µmol/L at End of Period 1 Among Participants With Baseline ≥600 µmol/L in the Low Dose BID Group

    Time frame: Baseline to End of Period 1 (Week 6)

  5. Percentage of Participants Achieving Plasma Phe <360 µmol/L at End of Period 1 in the Low Dose BID Group

    Time frame: Baseline to End of Period 1 (Week 6)

  6. Absolute Change in Plasma Phe From Baseline to the Mean of Weeks 2, 4, and 6 in the JNT-517 Low Dose BID Group at End of Period 1

    Time frame: Baseline to End of Period 1 (Week 6)

  7. Percent Change in Plasma Phe From Baseline to the Mean of Weeks 2, 4, and 6 in the JNT-517 Low Dose BID Group at End of Period 1

    Time frame: Baseline to End of Period 1 (Week 6)

  8. Change From Baseline in ADHD Rating Scale-5 (ADHD-RS-5) Inattentive Subscore in Participants With Baseline Inattentive Subscore More Than (>) 9 in the JNT-517 High Dose BID Group at End of Period 1

    The ADHD-RS-5 Inattentive Subscore (sum of 9 inattentive items) ranges from 0 to 27, with higher scores indicating greater severity of inattentive symptoms. A decrease in the subscore represents an improvement in symptoms.

    Time frame: Baseline to End of Period 1 (Week 6)

  9. Change From Baseline in Dietary Phe Intake While Achieving Plasma Phe <360 µmol/L at the End of Period 2 in Participants Receiving High Dose BID Group and Participating in the Diet Normalization

    Time frame: Baseline to end of Period 2 (Week 52)

  10. Number of Participants With Treatment-Emergent Adverse Events and Serious Treatment-Emergent Adverse Events in Periods 1 and 2

    Time frame: From first dose of the study drug through Week 56

  11. Percentage of Participants With More Than or Equal to (≥) 30 Percent (%) and ≥50% Reduction From Baseline in Plasma Phe at Week 6

    Time frame: Baseline to End of Period 1 (Week 6)

  12. Percentage of Participants Achieving Plasma Phe Less Than (<) 120 µmol/L at End of Period 1 in the High Dose BID and Low Dose BID Groups

    Time frame: End of Period 1 (Week 6)

  13. Absolute Change in Plasma Phe From Baseline to Weeks 2, 4, and 6 of Period 1 in the JNT-517 High Dose BID and Low Dose BID Groups

    Time frame: Baseline to End of Period 1 (Week 6)

  14. Percent Change in Plasma Phe From Baseline to Weeks 2, 4, and 6 of Period 1 in the JNT-517 High Dose BID and Low Dose BID Groups

    Time frame: Baseline to End of Period 1 (Week 6)

  15. Percentage of Participants Achieving Plasma Phe <600 µmol/L Among Participants With Baseline ≥600 µmol/L in the JNT-517 High Dose BID and Low Dose BID Dose Groups at the End of Period 2

    Time frame: Baseline to End of Period 2 (Week 52)

  16. Percentage of Participants Achieving Plasma Phe <360 µmol/L in the JNT-517 High Dose BID and Low Dose BID Dose Groups at the End of Period 2

    Time frame: End of Period 2 (Week 52)

  17. Percentage of Participants Achieving Plasma Phe <120 µmol/L in the JNT-517 High Dose BID and Low Dose BID Dose Groups at the End of Period 2

    Time frame: End of Period 2 (Week 52)

  18. Absolute Change From Baseline in Plasma Phe in the JNT-517 Low Dose BID and High Dose BID Dose Groups During Period 2

    Time frame: Baseline to End of Period 2 (Week 52)

  19. Percent Change From Baseline in Plasma Phe in the JNT-517 Low Dose BID and High Dose BID Dose Groups During Period 2

    Time frame: Baseline to End of Period 2 (Week 52)

  20. Percentage of Participants With ≥30% and ≥50% Reduction From Baseline in Plasma Phe During Period 2

    Time frame: Baseline to End of Period 2 (Week 52)

  21. Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Stop Signal Reaction Time at End of Period 1

    The CANTAB Stop Signal Task measures response inhibition. Stop Signal Reaction Time (SSRT) reflects the time required to inhibit a response, with longer times indicating poorer inhibitory control. A decrease from baseline indicates improvement.

    Time frame: Baseline to End of Period 1 (Week 6)

  22. Change From Baseline in ADHD-RS-5 Inattentive Subscore in Participants With Baseline Inattentive Subscore > 9 in the JNT-517 Low Dose BID Group at End of Period 1

    The ADHD-RS-5 Inattentive Subscore (sum of 9 inattentive items) ranges from 0 to 27, with higher scores indicating greater severity of inattentive symptoms. A decrease in the subscore represents an improvement in symptoms.

    Time frame: Baseline to End of Period 1 (Week 6)

  23. Change From Baseline in CANTAB Stop Signal Reaction Time During Period 2

    The CANTAB Stop Signal Task measures response inhibition. SSRT reflects the time required to inhibit a response, with longer times indicating poorer inhibitory control. A decrease from baseline indicates improvement.

    Time frame: Baseline to End of Period 2 (Week 52)

  24. Change From Baseline in ADHD Rating Scale-5 (ADHD-RS-5) Inattentive Subscore in Participants with Baseline Inattentive Subscore >9 in the JNT-517 High Dose BID and Low Dose BID Dose Groups During Period 2

    The ADHD Rating Scale-5 (ADHD-RS-5) Inattentive Subscore (sum of 9 inattentive items) ranges from 0 to 27, with higher scores indicating greater severity of inattentive symptoms. A decrease in the subscore represents an improvement in symptoms.

    Time frame: Baseline to End of Period 2 (Week 52)

  25. Change From Baseline in Adult Self-rating Scale (ASRS) for Attention Deficit Hyperactivity Disorder in Participants Aged ≥12 years at Screening in Both JNT 517 Dose Groups During Periods 1 and 2

    The ASRS has 18 questions covering two dimensions: attention deficits and hyperactive/impulsive behavior. Responses are rated on frequency using options like 'never,' 'rarely,' 'sometimes,' 'often,' or 'very frequently.' Each item scores from 0 (no problem) to 4 (most severe). The total ASRS score is the sum of all item scores ranging from 0 to 72, and higher scores indicate a high likelihood of ADHD.

    Time frame: From first dose of the study drug through Week 56

  26. Change From Baseline in Dietary Protein Intake While Maintaining Plasma Phe <360 µmol/L

    Time frame: Baseline to End of Period 2 (Week 52)

  27. Percentage of Participants Achieving Recommended Dietary Allowance (RDA) for Natural Intact Protein Intake While Maintaining Plasma Phenylalanine <360 µmol/L

    Time frame: End of Period 2 (Week 52)

  28. Percentage of Participants Achieving Two Times the RDA for Natural Intact Protein Intake Consistent With an Unrestricted Diet While Maintaining Plasma Phenylalanine <360 µmol/L

    Time frame: End of Period 2 (Week 52)

07

Study locations

26 of 26 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Mar 2028, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2025
First posted
May 14, 2025
StartActual
Oct 20, 2025
Primary completionEst.
Mar 1, 2028
CompletionEst.
Apr 1, 2028
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Fujita Health University · Toyoake, Japan
Show 1 removed
  • Fujita Health University · Kutsukake-cho, Japan
Oct 21, 2026
Eligibility
Minimum age 18 Years→4 Years; Criteria largely rewritten (59 changes)
What changed in the criteria
  • RemovedInclusion Criteria:
  • RemovedMales and females ≥18 years of age on Day 1
  • RemovedClinical diagnosis of PKU
  • RemovedAverage of at least 3 plasma Phe levels (after >4-hour fast) during Screening period of ≥360 μmol/L
  • RemovedNot on pegvaliase within 4 weeks prior to Screening
  • RemovedIf on sapropterin or large neutral amino acids, such as PheBloc®, NeoPhe®, and PreKunil® at Screening, must be on a stable dose 4 weeks prior to Screening and for the entire study duration.
  • RemovedWilling and able to maintain a stable diet in Phe and total protein (intact protein and medical food protein) and able to adjust diet through the duration of the study according to the Dietary Management Guidelines
  • RemovedBody weight >40 kilograms (kg)
  • RemovedIf biologically female of childbearing potential:
  • RemovedMust have a negative serum pregnancy test at Screening and a negative urine pregnancy test by Day 1
  • RemovedMust practice sexual abstinence, or if involved in any sexual intercourse that could lead to pregnancy, must agree to use 2 highly effective contraceptive methods from Screening until at least 30 days after the last study drug administration
  • RemovedIf taking estrogen- or progesterone-based oral contraceptives, must agree to use 2 other highly effective methods of contraception or must agree to sexual abstinence during the study
  • RemovedMust refrain from donating ova during the course of the study and for 30 days after the last dose of the study drug.
  • RemovedIf a biologically female not of childbearing potential or postmenopausal, defined as follows:
  • RemovedHas had surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy)
  • RemovedHas had amenorrhea for minimum of 1 year with confirmation by levels of follicle stimulating hormone testing
  • RemovedHas not achieved menarche (has not had first menstrual period). If a female achieves menarche during the study, she will need to follow the contraception requirement for females of childbearing potential
  • RemovedIf biologically male, must practice sexual abstinence, or if involved in any sexual intercourse that could lead to pregnancy, must agree to use highly effective contraceptive methods from Day 1 until at least 30 days after the last study drug administration and must refrain from donating sperm during the course of the study and for 30 days after the last dose of the study drug NOTE: No restrictions are required for biological males who have undergone a documented vasectomy at least 4 months prior to Screening. If the vasectomy procedure is not documented or was performed less than 4 months prior to Screening, males must follow the same contraception as for non-vasectomized participants.
  • RemovedParticipants with psychiatric illness must be well-controlled for the last 6 months prior to the Screening visit and if on medication, on stable medications for the last 3 months.
  • RemovedCapable of giving signed informed consent or parent/legal guardian to provide informed consent and the participant to give assent and confirm able to comply with study procedures
  • RemovedExclusion Criteria:
  • RemovedExclusion Criteria
  • RemovedAny acute or uncontrolled chronic medical condition that would prevent the participant from complying with the procedures or place the participant at risk if they participate in the study
  • RemovedPositive for hepatitis B or C or human immunodeficiency virus
  • RemovedAny history of malignancy of any organ system (other than non-melanoma skin cancer or in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases
  • RemovedAny history of significant liver disease
  • RemovedAny history of cataracts or more than minimal cataracts observed during the Screening ophthalmologic examination. Minimal cataracts are defined as changes similar to lens opacities classification system III (LOCS III), lens grade C1, N1 or P1
  • RemovedAny surgical or medical conditions that may affect study drug absorption, distribution, metabolism, or excretion
  • RemovedEstimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 by 2021 Chronic Kidney Disease Epidemiology Collaboration formula
  • RemovedParticipation in another investigational drug trial within 30 days or, if known, 5 half-lives of the investigational drug (whichever is longer). For gene therapy or editing trials, participants must have received the intervention >6 months prior to Screening visit and with stable plasma Phe in the past 2 months prior to Screening visit.
  • RemovedAlcohol consumption within 5 days of randomization and/or unwilling to limit to 1 alcoholic drink per day until after the 6-month study visit
  • RemovedHistory of drug/alcohol abuse in the last year
  • RemovedUse of any medications that are inhibitors or inducers of cytochrome P450 (CYP3A4) or inhibitors of the transporter P-glycoprotein (P-gp) within 4 weeks prior to randomization and unwilling and/or unable to avoid these medications throughout the treatment duration
  • RemovedUse of any medications that are substrates of breast cancer resistance protein (BCRP), multidrug and toxin extrusion (MATE)1, or MATE2-K within 4 weeks prior to randomization and unwilling and/or unable to avoid these medications throughout the treatment duration NOTE: Participants will be permitted to continue with estrogen- or progesterone-based oral contraceptives, but must agree to use 2 other methods of contraception, where at least 1 must be highly effective, or must agree to sexual abstinence during the study.
  • RemovedCurrent, recent, or suspected active viral or bacterial infection within 2 weeks prior to and during the Screening Period
  • RemovedUnable to tolerate oral medication or have a condition that would interfere with the absorption of JNT-517
  • RemovedAny of the following laboratory values at the Screening visit: -Alanine aminotransferase or aspartate aminotransferase values >1.5× the upper limit of normal (ULN)-Total bilirubin ˃ULN unless history of Gilbert Syndrome and then total bilirubin >4 milligrams per deciliter (mg/dL) is exclusionary-Hemoglobin <11.0 grams per deciliter (g/dL) [<110.0 grams per liter (g/L)]-White blood cell count >ULN-Platelets <150 × 10\^9/Liter (L) (<150,000/cubic millimeters [mm\^3]).
Inclusion criteria
  • AddedMale or female participants aged 4 years or older.
  • AddedDiagnosed with phenylketonuria.
  • AddedHave phenylalanine levels that meet study requirements.

…and 19 more changes, on the record history on ClinicalTrials.gov ↗

Oct 21, 2026
Interventions
Changed JNT-517 Tablet→JNT-517; JNT-517 Tablet→JNT-517 Matching Placebo. Removed Drug: Placebo Tablet: BID. Arm changed Placebo - BID→Placebo. Arms added: JNT-517 - High Dose·JNT-517 - Low Dose; arms removed: Drug: JNT-517 - 150 mg BID (Tablet)·Drug: JNT-517 - 75 mg BID (Tablet)
Oct 21, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedAbsolute Change in Plasma Phenylalanine (Phe) From Baseline to the Mean of Weeks 2, 4, and 6 in the JNT-517 150 mgHigh Dose BID Dose Group at End of Period 1Time frame: Baseline to End of Period 1 (Week 6)
Oct 21, 2026
Secondary outcomes
18 edited, 4 added
What changed in the outcomes
  • EditedPercent Change in Plasma Phe From Baseline to the Mean of Weeks 2, 4, and 6 in the JNT-517 150 mgHigh Dose BID Dose Group at End of Period 1Time frame: Baseline to End of Period 1 (Week 6)
  • EditedPercentage of Participants Achieving Plasma Phe Less Than (<) 600 Micromoles per Liter (µmol/L) at End of Period 1 Among Participants With Baseline ≥600 µmol/L in the 150 mgHigh Dose BID and 75 mg BID GroupsGroupTime frame: Baseline to End of Period 1 (Week 6)
  • EditedPercentage of Participants Achieving Plasma Phe <360 µmol/L at End of Period 1 in the 150 mgHigh Dose BID and 75 mg BID GroupsGroupTime frame: Baseline to End of Period 1 (Week 6)
  • EditedAbsolute Change in Plasma Phe From Baseline to the Mean of Weeks 2, 4, and 6 in the JNT-517 75 mgLow Dose BID Group at End of Period 1Time frame: Baseline to End of Period 1 (Week 6)
  • EditedPercent Change in Plasma Phe From Baseline to the Mean of Weeks 2, 4, and 6 in the JNT-517 75 mgLow Dose BID Group at End of Period 1Time frame: Baseline to End of Period 1 (Week 6)
  • EditedChange From Baseline in ADHD Rating Scale-5 (ADHD-RS-5) Inattentive Subscore in Participants With Baseline Inattentive Subscore More Than (>) 9 in the JNT-517 150 mgHigh Dose BID and 75 mg BID dose GroupsGroup at End of Period 1Time frame: Baseline to End of Period 1 (Week 6)
  • EditedChange From Baseline in Dietary Phe Intake While Achieving Plasma Phe <360 µmol/L at the End of Period 2 in Participants Receiving High Dose BID Group and Participating in the Diet NormalizationTime frame: Baseline to End of Period 1 (Week 6) → Baseline to end of Period 2 (Week 52)
  • EditedNumber of Participants With Treatment-Emergent Adverse Events and Serious Treatment-Emergent Adverse Events in Periods 1 and 2Time frame: From first dose of the study drug through Week 56
  • EditedPercentage of Participants With More Than or Equal to (≥) 30 Percent (%) and ≥50% Reduction From Baseline in Plasma Phe at Week 6Time frame: Baseline to End of Period 1 (Week 6)
  • EditedPercentage of Participants Achieving Plasma Phe <120600 µmol/L at End of Period 1 Among Participants With Baseline ≥600 µmol/L in the 150 mgLow Dose BID and 75 mg BID GroupsGroupTime frame: End of Period 1 (Week 6) → Baseline to End of Period 1 (Week 6)
  • EditedAbsolute Change in Plasma Phe From Baseline to Weeks 2, 4, and 6 of Period 1 in the JNT-517 150 mgHigh Dose BID and 75 mgLow Dose BID GroupsTime frame: Baseline to End of Period 1 (Week 6)
  • EditedPercent Change in Plasma Phe From Baseline to Weeks 2, 4, and 6 of Period 1 in the JNT-517 150 mgHigh Dose BID and 75 mgLow Dose BID GroupsTime frame: Baseline to End of Period 1 (Week 6)
  • EditedPercentage of Participants Achieving Plasma Phe <600 µmol/L Among Participants With Baseline ≥600 µmol/L in the JNT-517 150 mgHigh Dose BID and 75 mgLow Dose BID Dose Groups at the End of Period 2Time frame: Baseline to End of Period 2 (Week 52)
  • EditedPercentage of Participants Achieving Plasma Phe <360 µmol/L in the JNT-517 150 mg BID and 75 mg BID Dose Groups at the End of Period 21 in the Low Dose BID GroupTime frame: End of Period 2 (Week 52) → Baseline to End of Period 1 (Week 6)
  • EditedPercentage of Participants Achieving Plasma Phe <120360 µmol/L in the JNT-517 150 mgHigh Dose BID and 75 mgLow Dose BID Dose Groups at the End of Period 2Time frame: End of Period 2 (Week 52)
  • EditedAbsolute Change From Baseline inPercentage of Participants Achieving Plasma Phe <120 µmol/L in the JNT-517 75 mgHigh Dose BID and 150 mgLow Dose BID Dose Groups Duringat the End of Period 2Time frame: Baseline to End of Period 2 (Week 52) → End of Period 2 (Week 52)
  • EditedPercentAbsolute Change From Baseline in Plasma Phe in the JNT-517 75 mgLow Dose BID and 150 mgHigh Dose BID Dose Groups During Period 2Time frame: Baseline to End of Period 2 (Week 52)
  • EditedPercent Change From Baseline in ADHD Rating Scale-5 (ADHD-RS-5) Inattentive Subscore in Participants with Baseline Inattentive Subscore >9Plasma Phe in the JNT-517 150 mgLow Dose BID and 75 mgHigh Dose BID Dose Groups During Period 2Time frame: Baseline to End of Period 2 (Week 52)
  • AddedPercentage of Participants Achieving Plasma Phe Less Than (<) 120 µmol/L at End of Period 1 in the High Dose BID and Low Dose BID GroupsTime frame: End of Period 1 (Week 6)
  • AddedChange From Baseline in ADHD-RS-5 Inattentive Subscore in Participants With Baseline Inattentive Subscore > 9 in the JNT-517 Low Dose BID Group at End of Period 1Time frame: Baseline to End of Period 1 (Week 6)
  • AddedChange From Baseline in ADHD Rating Scale-5 (ADHD-RS-5) Inattentive Subscore in Participants with Baseline Inattentive Subscore >9 in the JNT-517 High Dose BID and Low Dose BID Dose Groups During Period 2Time frame: Baseline to End of Period 2 (Week 52)
  • AddedChange From Baseline in Adult Self-rating Scale (ASRS) for Attention Deficit Hyperactivity Disorder in Participants Aged ≥12 years at Screening in Both JNT 517 Dose Groups During Periods 1 and 2Time frame: From first dose of the study drug through Week 56
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    1 site added, 1 site removed
    Show site
    • Fujita Health University · Toyoake, Japan
    Show 1 removed
    • Fujita Health University · Kutsukake-cho, Japan
    Eligibility Minimum age 18 Years→4 Years; Criteria largely rewritten (59 changes)
    What changed in the criteria
    • RemovedInclusion Criteria:
    • RemovedMales and females ≥18 years of age on Day 1
    • RemovedClinical diagnosis of PKU
    • RemovedAverage of at least 3 plasma Phe levels (after >4-hour fast) during Screening period of ≥360 μmol/L
    • RemovedNot on pegvaliase within 4 weeks prior to Screening
    • RemovedIf on sapropterin or large neutral amino acids, such as PheBloc®, NeoPhe®, and PreKunil® at Screening, must be on a stable dose 4 weeks prior to Screening and for the entire study duration.
    • RemovedWilling and able to maintain a stable diet in Phe and total protein (intact protein and medical food protein) and able to adjust diet through the duration of the study according to the Dietary Management Guidelines
    • RemovedBody weight >40 kilograms (kg)
    • RemovedIf biologically female of childbearing potential:
    • RemovedMust have a negative serum pregnancy test at Screening and a negative urine pregnancy test by Day 1
    • RemovedMust practice sexual abstinence, or if involved in any sexual intercourse that could lead to pregnancy, must agree to use 2 highly effective contraceptive methods from Screening until at least 30 days after the last study drug administration
    • RemovedIf taking estrogen- or progesterone-based oral contraceptives, must agree to use 2 other highly effective methods of contraception or must agree to sexual abstinence during the study
    • RemovedMust refrain from donating ova during the course of the study and for 30 days after the last dose of the study drug.
    • RemovedIf a biologically female not of childbearing potential or postmenopausal, defined as follows:
    • RemovedHas had surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy)
    • RemovedHas had amenorrhea for minimum of 1 year with confirmation by levels of follicle stimulating hormone testing
    • RemovedHas not achieved menarche (has not had first menstrual period). If a female achieves menarche during the study, she will need to follow the contraception requirement for females of childbearing potential
    • RemovedIf biologically male, must practice sexual abstinence, or if involved in any sexual intercourse that could lead to pregnancy, must agree to use highly effective contraceptive methods from Day 1 until at least 30 days after the last study drug administration and must refrain from donating sperm during the course of the study and for 30 days after the last dose of the study drug NOTE: No restrictions are required for biological males who have undergone a documented vasectomy at least 4 months prior to Screening. If the vasectomy procedure is not documented or was performed less than 4 months prior to Screening, males must follow the same contraception as for non-vasectomized participants.
    • RemovedParticipants with psychiatric illness must be well-controlled for the last 6 months prior to the Screening visit and if on medication, on stable medications for the last 3 months.
    • RemovedCapable of giving signed informed consent or parent/legal guardian to provide informed consent and the participant to give assent and confirm able to comply with study procedures
    • RemovedExclusion Criteria:
    • RemovedExclusion Criteria
    • RemovedAny acute or uncontrolled chronic medical condition that would prevent the participant from complying with the procedures or place the participant at risk if they participate in the study
    • RemovedPositive for hepatitis B or C or human immunodeficiency virus
    • RemovedAny history of malignancy of any organ system (other than non-melanoma skin cancer or in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases
    • RemovedAny history of significant liver disease
    • RemovedAny history of cataracts or more than minimal cataracts observed during the Screening ophthalmologic examination. Minimal cataracts are defined as changes similar to lens opacities classification system III (LOCS III), lens grade C1, N1 or P1
    • RemovedAny surgical or medical conditions that may affect study drug absorption, distribution, metabolism, or excretion
    • RemovedEstimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 by 2021 Chronic Kidney Disease Epidemiology Collaboration formula
    • RemovedParticipation in another investigational drug trial within 30 days or, if known, 5 half-lives of the investigational drug (whichever is longer). For gene therapy or editing trials, participants must have received the intervention >6 months prior to Screening visit and with stable plasma Phe in the past 2 months prior to Screening visit.
    • RemovedAlcohol consumption within 5 days of randomization and/or unwilling to limit to 1 alcoholic drink per day until after the 6-month study visit
    • RemovedHistory of drug/alcohol abuse in the last year
    • RemovedUse of any medications that are inhibitors or inducers of cytochrome P450 (CYP3A4) or inhibitors of the transporter P-glycoprotein (P-gp) within 4 weeks prior to randomization and unwilling and/or unable to avoid these medications throughout the treatment duration
    • RemovedUse of any medications that are substrates of breast cancer resistance protein (BCRP), multidrug and toxin extrusion (MATE)1, or MATE2-K within 4 weeks prior to randomization and unwilling and/or unable to avoid these medications throughout the treatment duration NOTE: Participants will be permitted to continue with estrogen- or progesterone-based oral contraceptives, but must agree to use 2 other methods of contraception, where at least 1 must be highly effective, or must agree to sexual abstinence during the study.
    • RemovedCurrent, recent, or suspected active viral or bacterial infection within 2 weeks prior to and during the Screening Period
    • RemovedUnable to tolerate oral medication or have a condition that would interfere with the absorption of JNT-517
    • RemovedAny of the following laboratory values at the Screening visit: -Alanine aminotransferase or aspartate aminotransferase values >1.5× the upper limit of normal (ULN)-Total bilirubin ˃ULN unless history of Gilbert Syndrome and then total bilirubin >4 milligrams per deciliter (mg/dL) is exclusionary-Hemoglobin <11.0 grams per deciliter (g/dL) [<110.0 grams per liter (g/L)]-White blood cell count >ULN-Platelets <150 × 10\^9/Liter (L) (<150,000/cubic millimeters [mm\^3]).
    Inclusion criteria
    • AddedMale or female participants aged 4 years or older.
    • AddedDiagnosed with phenylketonuria.
    • AddedHave phenylalanine levels that meet study requirements.

    …and 19 more changes, on the record history on ClinicalTrials.gov ↗

    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedAbsolute Change in Plasma Phenylalanine (Phe) From Baseline to the Mean of Weeks 2, 4, and 6 in the JNT-517 150 mgHigh Dose BID Dose Group at End of Period 1Time frame: Baseline to End of Period 1 (Week 6)
    Secondary outcomes 18 edited, 4 added
    What changed in the outcomes
    • EditedPercent Change in Plasma Phe From Baseline to the Mean of Weeks 2, 4, and 6 in the JNT-517 150 mgHigh Dose BID Dose Group at End of Period 1Time frame: Baseline to End of Period 1 (Week 6)
    • EditedPercentage of Participants Achieving Plasma Phe Less Than (<) 600 Micromoles per Liter (µmol/L) at End of Period 1 Among Participants With Baseline ≥600 µmol/L in the 150 mgHigh Dose BID and 75 mg BID GroupsGroupTime frame: Baseline to End of Period 1 (Week 6)
    • EditedPercentage of Participants Achieving Plasma Phe <360 µmol/L at End of Period 1 in the 150 mgHigh Dose BID and 75 mg BID GroupsGroupTime frame: Baseline to End of Period 1 (Week 6)
    • EditedAbsolute Change in Plasma Phe From Baseline to the Mean of Weeks 2, 4, and 6 in the JNT-517 75 mgLow Dose BID Group at End of Period 1Time frame: Baseline to End of Period 1 (Week 6)
    • EditedPercent Change in Plasma Phe From Baseline to the Mean of Weeks 2, 4, and 6 in the JNT-517 75 mgLow Dose BID Group at End of Period 1Time frame: Baseline to End of Period 1 (Week 6)
    • EditedChange From Baseline in ADHD Rating Scale-5 (ADHD-RS-5) Inattentive Subscore in Participants With Baseline Inattentive Subscore More Than (>) 9 in the JNT-517 150 mgHigh Dose BID and 75 mg BID dose GroupsGroup at End of Period 1Time frame: Baseline to End of Period 1 (Week 6)
    • EditedChange From Baseline in Dietary Phe Intake While Achieving Plasma Phe <360 µmol/L at the End of Period 2 in Participants Receiving High Dose BID Group and Participating in the Diet NormalizationTime frame: Baseline to End of Period 1 (Week 6) → Baseline to end of Period 2 (Week 52)
    • EditedNumber of Participants With Treatment-Emergent Adverse Events and Serious Treatment-Emergent Adverse Events in Periods 1 and 2Time frame: From first dose of the study drug through Week 56
    • EditedPercentage of Participants With More Than or Equal to (≥) 30 Percent (%) and ≥50% Reduction From Baseline in Plasma Phe at Week 6Time frame: Baseline to End of Period 1 (Week 6)
    • EditedPercentage of Participants Achieving Plasma Phe <120600 µmol/L at End of Period 1 Among Participants With Baseline ≥600 µmol/L in the 150 mgLow Dose BID and 75 mg BID GroupsGroupTime frame: End of Period 1 (Week 6) → Baseline to End of Period 1 (Week 6)
    • EditedAbsolute Change in Plasma Phe From Baseline to Weeks 2, 4, and 6 of Period 1 in the JNT-517 150 mgHigh Dose BID and 75 mgLow Dose BID GroupsTime frame: Baseline to End of Period 1 (Week 6)
    • EditedPercent Change in Plasma Phe From Baseline to Weeks 2, 4, and 6 of Period 1 in the JNT-517 150 mgHigh Dose BID and 75 mgLow Dose BID GroupsTime frame: Baseline to End of Period 1 (Week 6)
    • EditedPercentage of Participants Achieving Plasma Phe <600 µmol/L Among Participants With Baseline ≥600 µmol/L in the JNT-517 150 mgHigh Dose BID and 75 mgLow Dose BID Dose Groups at the End of Period 2Time frame: Baseline to End of Period 2 (Week 52)
    • EditedPercentage of Participants Achieving Plasma Phe <360 µmol/L in the JNT-517 150 mg BID and 75 mg BID Dose Groups at the End of Period 21 in the Low Dose BID GroupTime frame: End of Period 2 (Week 52) → Baseline to End of Period 1 (Week 6)
    • EditedPercentage of Participants Achieving Plasma Phe <120360 µmol/L in the JNT-517 150 mgHigh Dose BID and 75 mgLow Dose BID Dose Groups at the End of Period 2Time frame: End of Period 2 (Week 52)
    • EditedAbsolute Change From Baseline inPercentage of Participants Achieving Plasma Phe <120 µmol/L in the JNT-517 75 mgHigh Dose BID and 150 mgLow Dose BID Dose Groups Duringat the End of Period 2Time frame: Baseline to End of Period 2 (Week 52) → End of Period 2 (Week 52)
    • EditedPercentAbsolute Change From Baseline in Plasma Phe in the JNT-517 75 mgLow Dose BID and 150 mgHigh Dose BID Dose Groups During Period 2Time frame: Baseline to End of Period 2 (Week 52)
    • EditedPercent Change From Baseline in ADHD Rating Scale-5 (ADHD-RS-5) Inattentive Subscore in Participants with Baseline Inattentive Subscore >9Plasma Phe in the JNT-517 150 mgLow Dose BID and 75 mgHigh Dose BID Dose Groups During Period 2Time frame: Baseline to End of Period 2 (Week 52)
    • AddedPercentage of Participants Achieving Plasma Phe Less Than (<) 120 µmol/L at End of Period 1 in the High Dose BID and Low Dose BID GroupsTime frame: End of Period 1 (Week 6)
    • AddedChange From Baseline in ADHD-RS-5 Inattentive Subscore in Participants With Baseline Inattentive Subscore > 9 in the JNT-517 Low Dose BID Group at End of Period 1Time frame: Baseline to End of Period 1 (Week 6)
    • AddedChange From Baseline in ADHD Rating Scale-5 (ADHD-RS-5) Inattentive Subscore in Participants with Baseline Inattentive Subscore >9 in the JNT-517 High Dose BID and Low Dose BID Dose Groups During Period 2Time frame: Baseline to End of Period 2 (Week 52)
    • AddedChange From Baseline in Adult Self-rating Scale (ASRS) for Attention Deficit Hyperactivity Disorder in Participants Aged ≥12 years at Screening in Both JNT 517 Dose Groups During Periods 1 and 2Time frame: From first dose of the study drug through Week 56
    Interventions Changed JNT-517 Tablet→JNT-517; JNT-517 Tablet→JNT-517 Matching Placebo. Removed Drug: Placebo Tablet: BID. Arm changed Placebo - BID→Placebo. Arms added: JNT-517 - High Dose·JNT-517 - Low Dose; arms removed: Drug: JNT-517 - 150 mg BID (Tablet)·Drug: JNT-517 - 75 mg BID (Tablet)
    + 4 other changes: identifiers, verification date, description and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06971731
Responsible party
Sponsor
First posted
May 14, 2025
Start date
Oct 20, 2025
Primary completion
Mar 1, 2028 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Oct 21, 2026

Study contacts

Otsuka Call Center
Contact
Otsuka-ProfessionalServices@otsuka-us.com
844-687-8522

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Repinatrabit

Start the discussion